Psychiatric Disorders clinical trials

Explore recruiting psychiatric disorders clinical trials.

Recruiting psychiatric disorders studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Psychiatric Disorders trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Cannabidiol in refractory childhood epilepsy, a personalized high-quality approach

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Cannabidiol for reducing drinking in alcohol use disorder and modifying the effects of alcohol on the brain and the liver: a phase 2 clinical trial.- The CARAMEL Study

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Safety and pharmacokinetics of antipsychotics in children 2: Studying TDM in an RCT

Netherlands, Germany

Therapeutic use (Phase IV) EU CTIS Study details

Efficacy of melatonin, low-dose quetiapine, or placebo in patients with psychiatric disorders and comorbid insomnia: a randomized clinical trial

Denmark

Phase II and Phase III (Integrated) EU CTIS Study details

Efficacy of melatonin, low-dose quetiapine, or placebo in adolescents with psychiatric disorders and comorbid insomnia: a randomized clinical trial

Denmark

Phase II and Phase III (Integrated) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-center Study to Compare the Anti-Depressive Efficacy and Safety of Samyr® IM versus Placebo IM as an Enhancer Adjunctive to Antidepressant Treatment in Major Depression Disorder Patients Who have not Experienced Sufficient Symptoms Improvement Despite Antidepressant Treatment

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Psychiatric Disorders trials by city

Psychiatric Disorders in Toronto Psychiatric Disorders in Vancouver Psychiatric Disorders in Montreal Psychiatric Disorders in Calgary Psychiatric Disorders in Edmonton Psychiatric Disorders in Ottawa Psychiatric Disorders in Winnipeg Psychiatric Disorders in Quebec City Psychiatric Disorders in Hamilton Psychiatric Disorders in Kitchener Psychiatric Disorders in London Psychiatric Disorders in Halifax Psychiatric Disorders in New York Psychiatric Disorders in Los Angeles Psychiatric Disorders in Chicago Psychiatric Disorders in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease